CD8A and neoplasm: In our experiment, the ratio of CD8/Treg was recovered significantly after pexidartinib (PLX3397) combined with αPD-1 (Figures 4E,H), which also indicated that pexidartinib could regulate CD8+ T cell function in tumor microenvironment.